Stockscreener 앱 받기
8.05
4.14%
0.32
시간 외 거래:
8.01
-0.04
-0.50%
전일 마감가:
$7.73
열려 있는:
$7.85
하루 거래량:
1.16M
Relative Volume:
0.84
시가총액:
$631.46M
수익:
$311.71M
순이익/손실:
$163.05M
주가수익비율:
4.0585
EPS:
1.9835
순현금흐름:
$172.79M
1주 성능:
+7.62%
1개월 성능:
+13.70%
6개월 성능:
-25.32%
1년 성능:
-27.87%
1일 변동 폭
$7.81
$8.1143
1주일 범위
$7.51
$8.1143
52주 변동 폭
$6.125
$17.43
CorMedix Inc Stock (CRMD) Company Profile
명칭
CorMedix Inc
전화
908-517-9500
주소
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
8.05 | 606.36M | 311.71M | 163.05M | 172.79M | 1.9835 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 업그레이드 | D. Boral Capital | Hold → Buy |
| 2025-06-30 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2025-06-30 | 개시 | H.C. Wainwright | Buy |
| 2025-03-07 | 개시 | Leerink Partners | Outperform |
| 2025-01-13 | 개시 | D. Boral Capital | Buy |
| 2024-08-26 | 개시 | Rodman & Renshaw | Buy |
| 2023-08-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-02-17 | 개시 | Needham | Buy |
| 2020-09-29 | 개시 | JMP Securities | Mkt Outperform |
| 2020-09-21 | 개시 | Truist | Buy |
| 2019-12-18 | 개시 | B. Riley FBR | Buy |
| 2019-03-26 | 재확인 | H.C. Wainwright | Buy |
| 2018-12-06 | 개시 | ROTH Capital | Buy |
| 2017-09-25 | 재확인 | H.C. Wainwright | Buy |
| 2017-08-10 | 재확인 | Rodman & Renshaw | Buy |
| 2017-05-05 | 재확인 | Rodman & Renshaw | Buy |
| 2016-11-11 | 재확인 | FBR & Co. | Outperform |
| 2016-03-17 | 재확인 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | FBR Capital | Outperform |
| 2015-11-16 | 재확인 | ROTH Capital | Neutral |
| 2015-10-29 | 재확인 | ROTH Capital | Neutral |
| 2015-05-06 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2014-12-08 | 재확인 | ROTH Capital | Buy |
| 2011-10-03 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
CorMedix Inc 주식(CRMD)의 최신 뉴스
What CorMedix says before the bell May 14: earnings and update - Stock Titan
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026 - Yahoo Finance
CorMedix stock falls 5% on fourth quarter earnings miss - Investing.com
Cormedix Stock Pre-Market (+6.2%) : Technical Move Ahead of Key Q2 Catalyst - Trefis
CorMedix reports Q4 revenue of $128.6M, reaffirms 2026 guidance - Investing.com
CorMedix banks on DefenCath sales in Q4 as Melinta adds upside - MSN
CRMD News | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
HC Wainwright & Co. Maintains CorMedix (CRMD) Buy Recommendation - MSN
[ARS] CorMedix Inc. SEC Filing - Stock Titan
CorMedix (CRMD) posts 2025 profit, seeks approval of key charter and governance changes - Stock Titan
CorMedix | 4: Statement of changes in beneficial ownership of securities-Officer Hurlburt Elizabeth - Moomoo
H.C. Wainwright reiterates CorMedix stock rating on trial results By Investing.com - Investing.com India
Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating - Moomoo
CorMedix stock rating maintained at outperform by Citizens By Investing.com - Investing.com India
A Quick Look at Today's Ratings for CorMedix(CRMD.US), With a Forecast Between $13 to $15 - Moomoo
H.C. Wainwright reiterates CorMedix stock rating on trial results - Investing.com UK
H.C. Wainwright Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $13 - Moomoo
RBC Raises Price Target on CorMedix to $14 From $13, Keeps Outperform, Speculative Risk - marketscreener.com
CorMedix stock rating maintained at outperform by Citizens - Investing.com Australia
symbol__ Stock Quote Price and Forecast - CNN
Positive REZZAYO Phase III Prophylaxis Data Might Change The Case For Investing In CorMedix (CRMD) - Sahm
Cormedix Stock Soars Pre-Market After Earnings Beat, Higher Full-Year Guidance - MSN
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Raises Target Price to $15 - Moomoo
CorMedix reports positive Phase III results for rezafungin trial - Investing.com UK
RBC Capital raises CorMedix stock price target on phase III data - Investing.com UK
RBC Capital raises CorMedix stock price target on phase III data By Investing.com - Investing.com South Africa
CorMedix files to sell 6.32M shares of common stock for holders - MSN
CorMedix nears an 11-month low after earnings miss - MSN
CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study - Benzinga
CorMedix Announces Positive Phase III Results for Rezafungin in Preventing Invasive Fungal Diseases in Stem Cell Transplant Patients - Minichart
Cormedix Therapeutics announces positive topline results from phase III Respect trial - marketscreener.com
Cormedix Therapeutics Announces Positive Topline Results From Phase Iii Respect Trial - TradingView
CorMedix reports positive Phase III results for rezafungin trial By Investing.com - Investing.com South Africa
Phase III ReSPECT success boosts CorMedix (CRMD) REZZAYO prophylaxis plans - Stock Titan
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients - ChartMill
CorMedix shares slip after unveiling lower revenue outlook for 2026 - MSN
(CRMD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Do options traders know something about CorMedix stock we don't? - MSN
CRMD Stock Price, Quote & Chart | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
CorMedix Inc (CRMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):